ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 1.04 (+5.05%) as of
Key statistics
- Market cap
- 10.28M
- Forward P/E
- -0.05
- EPS (TTM)
- -4.3500
- Dividend yield
- 0.00%
- 52-week range
- 0.8800 – 19.5400
- Beta
- 2.21
- Revenue (TTM)
- 24.25M
- Profit margin
- -148.11%
- Analyst target
- SEK 4.00
- Volume
- 77.81k
About ExpreS2ion Biotech Holding AB (publ)
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Helsingborg, Sweden
- Employees
- 19
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.